問卷

TPIDB > Study Site

Study Site



Shin Kong Memorial Wu Ho-Su Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 111Taipei CityShih Lin

篩選

List

142Cases

2019-12-01 - 2030-05-31

Phase III

Active
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia
  • Condition/Disease

    Essential Thrombocythemia

  • Test Drug

    Ropeginterferon alfa-2b (P1101)

Participate Sites
23Sites

Not yet recruiting3Sites

Recruiting20Sites

2023-12-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-05-10 - 2025-04-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2025-03-01 - 2029-03-01

Phase III

Active
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study
  • Condition/Disease

    Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study

  • Test Drug

    injection

Participate Sites
14Sites

Recruiting14Sites

2010-10-01 - 2012-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-04-01 - 2012-04-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2005-03-01 - 2006-03-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites